Pfizer Has A New Anti-COVID Concoction In The Works

This past Friday, Pfizer, one of the drug companies known for its vaccine for COVID-19, announced the findings from an interim analysis that supposedly shows that its new pill that has been designed to treat COVID-19 mitigated the risk of death or hospitalization from the disease by roughly 89%.

The company stated in its announcement:

  • PAXLOVID™ […] was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19
  • In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo
  • Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. [Food and Drug Administration] for Emergency Use Authorization (EUA) as soon as possible

“Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic. These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” stated the Chairman and Chief Executive Officer of Pfizer, Albert Bourla. “Given the continued global impact of COVID-19, we have remained laser-focused on the science and fulfilling our responsibility to help healthcare systems and institutions around the world while ensuring equitable and broad access to people everywhere.”

Very Best Bumperstickers 600 x 300

“All of us at Pfizer are incredibly proud of our scientists, who designed and developed this molecule, working with the utmost urgency to help lessen the impact of this devastating disease on patients and their communities,” stated Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer,  Mikael Dolsten, MD, PhD. “We’re thankful to all of the patients, investigators, and sites around the world who participated in this clinical trial, all with the common goal of bringing forth a breakthrough oral therapy to help combat COVID-19.”

As reported by the BBC, “The drug – Paxlovid – is intended for use soon after symptoms develop in people at high risk of severe disease.”

The company also went on to note that per “the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA),” it stopped further enrollment into its study due to the “overwhelming efficacy demonstrated in these results …”

In an announcement put forth on Friday, Old Uncle Joe stated, “If authorized by the FDA we may soon have pills that treat the virus in those who become infected,” also stating. “We’ve already secured millions of doses. The therapy would be another tool in our toolbox to protect people from the worst outcomes of COVID.”

Also on Friday, the BBC stated that “the UK has already ordered 250,000 courses of the new Pfizer treatment, which has not yet been approved, along with another 480,000 courses of MSD’s molnupiravir pill.”

Forbes has also stated that the U.S. has also “committed to buying 1.7 million courses of molnupiravir if it gets approved by the FDA for emergency use.”

You Might Like

We have no tolerance for comments containing violence, racism, vulgarity, profanity, all caps, or discourteous behavior. Thank you for partnering with us to maintain a courteous and useful public environment where we can engage in reasonable discourse.